Basic Information

Gene symbol PDGFB Synonyms IBGC5, PDGF-2, PDGF2, SIS, SSV, c-sis Type of gene protein-coding
Description platelet derived growth factor subunit B

GTO ID GTC0094
Trial ID NCT01089517
Disease Age-Related Macular Degeneration
Altered gene PDGFB
Therapeutic/Target gene Target gene
TherapyAptamer
Treatment E10030|Fovista|anti-PDGF BB
Co-treatment Lucentis
PhasePhase2
Recruitment statusCompleted
TitleA Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration
Year2010
CountryUnited States
Company sponsorOphthotech Corporation
Other ID(s)OPH1001

Clinical Result

Cohort1: dose level 1
Administration route intravitreal injection
Dosage 0.3 mg
Pts 147
Age Adult, Older_Adult
Outcome The primary efficacy endpoint is the mean change in visual acuity from baseline at the Week 24 visit. Mean (Standard Error) = 8.8(1.09)
Adverse reactions 14/149(Cardiac disorders; Eye disorders; Gastrointestinal disorders; Infections and infestations; Neoplasms benign, malignant and unspecified, incl cysts and polyps; Nervous system disorders; Respiratory, thoracic and mediastinal disorders; Vascular disorders)
Cohort2: dose level 2
Administration route intravitreal injection
Dosage 1.5 mg
Pts 151
Age Adult, Older_Adult
Outcome The primary efficacy endpoint is the mean change in visual acuity from baseline at the Week 24 visit. Mean (Standard Error) = 10.6(1.07)
Adverse reactions 10/152(Cardiac disorders; Eye disorders; Gastrointestinal disorders; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified, incl cysts and polyps; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders; Vascular disorders)

Relationship Graph

Overview of Knowledge Graph